Modality
ERT
MOA
TROP-2 ADC
Target
AHR
Pathway
Ferroptosis
FSGS
Development Pipeline
Preclinical
~Nov 2019
→ ~Feb 2021
Phase 1
~May 2021
→ ~Aug 2022
Phase 2
Nov 2022
→ Aug 2027
Phase 2Current
NCT06012489
436 pts·FSGS
2022-11→2027-08·Completed
436 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-08-011.3y awayPh2 Data· FSGS
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P2
Complet…
Catalysts
Ph2 Data
2027-08-01 · 1.3y away
FSGS
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06012489 | Phase 2 | FSGS | Completed | 436 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR | |
| Doxalemzoparlimab | Nuvalent | Approved | AHR | |
| CRS-184 | CRISPR Therapeutics | Phase 1/2 | AHR | |
| Surarasimod | Xenon Pharma | Phase 2 | SHP2 | |
| Terazumab | Recursion | Phase 3 | AHR |